Year in Review | Published:

Osteoarthritis in 2016

Anti-NGF treatments for pain — two steps forward, one step back?

Nature Reviews Rheumatology volume 13, pages 7678 (2017) | Download Citation

Inhibitors of β-nerve growth factor (NGF) have impressive effects in reducing musculoskeletal pain, but have also been associated with adverse events of unclear aetiology. Several studies in the past year have sought to clarify the relative benefits and risks of anti-NGF treatment.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. 1.

    , & Structural, biological, and pharmacological strategies for the inhibition of nerve growth factor. Neurochem. Int. 6, 1266–1275 (2012).

  2. 2.

    & A systematic review of the efficacy and general safety of antibodies to NGF in the treatment of OA of the hip and knee. Osteoarthritis Cartilage 23 (Suppl. 1), S8–S17 (2015).

  3. 3.

    et al. Tanezumab for the treatment of pain from osteoarthritis of the knee. N. Engl. J. Med. 363, 1521–1531 (2010).

  4. 4.

    et al. When is osteonecrosis not osteonecrosis? Adjudication of reported serious adverse joint events in the tanezumab clinical development program. Arthritis Rheumatol. 68, 382–391 (2016).

  5. 5.

    et al. Efficacy and safety of fasinumab for osteoarthritic pain in patients with moderate to severe osteoarthritis of the knees or hips [abstract]. Arthritis Rheumatol. 68 (Suppl. 10), 295 (2016).

  6. 6.

    Regeneron Pharmaceuticals. Regeneron and Teva provide update on fasinumab clinical development programs. PR Newswire (2016).

  7. 7.

    et al. Nerve growth factor downregulates inflammatory response in human monocytes through TrkA. J. Immunol. 192, 3345–3354 (2014).

  8. 8.

    et al. Nerve growth factor is regulated by Toll-like receptor 2 in human intervertebral discs. J. Biol. Chem. 291, 3541–3551 (2016).

  9. 9.

    , , , & TLR2 is required for the altered transcription of p75NGF receptors in Gram positive infection. Neurochem. Res. 31, 297–301 (2006).

  10. 10.

    et al. Nerve growth factor promotes TLR4 signaling-induced maturation of human dendritic cells in vitro through inducible p75NTR 1. J. Immunol. 179, 6297–6304 (2007).

Download references

Author information


  1. Center for Musculoskeletal Health, Department of Medicine, University of California at Davis School of Medicine, 4625 2nd Avenue, Sacramento, California 95817, USA.

    • Nancy E. Lane
  2. Department of Medicine, University of California at San Diego, 9500 Gilman Drive, La Jolla, California 92093–0663, USA.

    • Maripat Corr


  1. Search for Nancy E. Lane in:

  2. Search for Maripat Corr in:

Competing interests

N.E.L. declares that she is a consultant to and advisory board member for Regeneron. M.C. declares no competing interests.

Corresponding author

Correspondence to Nancy E. Lane.

About this article

Publication history



Further reading

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing